

Contact

www.linkedin.com/in/dhanapalan-nagarathnam-4389a73 (LinkedIn)
www.dnaskinternational.com
(Company)

Top Skills

Medicinal Chemistry
Pharmaceuticals
Biotechnology

Languages

Tamil
English

Publications

Twelfth list of publications and presentations
Seventh list of publications and presentations
Second List of publications and presentations
Eighth List of Publications and presentations
Third list of publications and presentations

Patents

HCV and Cancer
Oncology, HCV and Cardiovascular
Oncology/ Kinase Inhibitors/ Cell Cycle Inhibitors
19. Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity. Dumas, J. P.; Boyer, S. J.; Joe, T. K.; Hatoum-Mokdad, H. N.; Kluender, H. C. E.; Lee, W.; Nagarathnam, D.; Sibley, R. N.; Su, N.
35. Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity. Dumas, J. P.; Boyer, S. J.; Joe, T. K.; Hatoum-Mokdad, H. N.; Kluender, H. C. E.; Lee, W.; Nagarathnam, D.; Sibley, R. N.; Su, N.

Dhanapalan Nagarathnam

President & CEO at MediVedaN Therapeutics
Bethany, Connecticut, United States

Summary

An accomplished drug discovery medicinal chemist with over 35 years of experience in drug discovery in many therapeutic areas, including HCV using nucleoside polymerase inhibitors, oncology using a variety of kinase inhibitors and cytotoxic agents, BPH, pain, diabetes, obesity using GPCR ligands, anti-infective agents, and ulcerative colitis. Inventor/co-inventor on over 75 issued patents and patent applications. Conducted pioneering research work in the areas of kinase inhibitors, multiple GPCR targets and on Zika virus. Author/presenter of over 80 peer reviewed publications in leading international journals and conferences. Invited speaker at multiple conferences and research centers. Played a leadership role and enjoy building highly productive drug discovery teams and my teams have put multiple compounds in clinical trials in multiple therapeutic areas.

Extensive experience working at/with biotechnologies such as Pharmasset (HCV), Synaptic/Lundbeck (GPCR), Onyx, Millennium, Rhizen, Novalex and large pharmaceutical companies such as Bayer Healthcare (Kinase Inhibitors), Merck, etc. In addition, Large scale manufacturing experience of drugs at TTK HealthCare and Malti-Chem Research Center.

Specialties: Drug discovery, Project Leader/Manager, Intellectual Property and Patent Applications, Competitive Intelligence, Due Diligence, Mentor/Trainer, Medicinal Chemistry, Synthetic Organic .

Experience

MediVedaN Therapeutics

President & CEO

January 2021 - Present (2 years 11 months)

52 Virginia Rail Drive, Bethany, CT 06524

Biotech conducting new drug discovery in the areas GVHD, Oncology, Virology and Stem Cell Research. We have multiple drug discovery programs

focused on getting much safer and effective treatments. We are open for new collaborations.

DNSK International, LLC.

14 years 5 months

President and CEO

January 2013 - Present (10 years 11 months)

Hamden, CT 06514

Collaborative drug discovery with biotech, pharmaceutical companies and universities in multiple therapeutic areas, including oncology, immunology, diabetes, virology, anti-infectives, inflammatory bowel diseases, etc.

Our first and major medicinal chemistry collaboration is with Rhizen Pharmaceuticals, Switzerland. I am pleased to work with them on their Scientific Advisory Board as a Medicinal Chemistry specialist.

Our most advanced co-invention product RP5264 (aka Umbralisib, TGR-1202) has been approved by the US FDA on February 5th, 2021 for the treatment of relapsed/refractory marginal zone lymphoma (MZL) and Follicular Lymphoma (FL). This compound is also in many more clinical trials.

<http://www.tgtherapeutics.com/pipeline/TGR-1202.cfm>

<http://www.rhizen.com/otxpipeline.html>

Second Product - RP6530, Best-in-class PI3K delta/gamma dual selective inhibitor is in many advanced stages of clinical trials. More details at <http://www.rhizen.com/otxpipeline.html>

Specialties: Drug discovery, Project Leader/Manager, Intellectual Property and Patent Applications, Competitive Intelligence, Due Diligence, Mentor/Trainer, Medicinal Chemistry, Synthetic Organic Chemistry, Parallel Synthesis, Lead Generation, Efficient Lead Optimization, Best-in-class Clinical Candidates, Process Research, Manufacturing, Optimized Drug Substance, Targeted Drug Discovery, CMC, Business Development, Global Collaborative Research and Drug Discovery, Oral, Inhaled, IV Drug Design, Structure/Fragment Based Drug Design, HCV, Oncology, Inflammation, BPH, Pain, Diabetes, Obesity, Anti-infectives, Ulcerative Colitis, Stem Cells, Respiratory, Kinase Inhibitors, Cytotoxic Agents, Polymerase Inhibitors, Protease Inhibitors, GPCR Antagonists/Agonists, Multi-step total synthesis of complex molecules, Peptides, Peptidomimetics, etc.

With these experiences, I would be happy to collaborate and work on many more Drug Discovery Projects

Vice President and Co-founder
July 2009 - Present (14 years 5 months)

Project Management with multiple international outsourcing companies.
Creation/Identification of New Drug Discovery Projects. Lead Generation, Lead Optimization, Generation Preclinical Candidates, Process Research, Metabolite ID and synthesis.
Consultation on improving the quality of candidates, research on follow-up candidates.

NorthEast BioLab
VP, Drug Discovery
May 2012 - Present (11 years 7 months)
Hamden, Connecticut

Please contact us for any of your Bioanalytical work needs. We have successfully supported several drugs that successfully reached market. We can help you design and get metabolically more stable and new products. Please check us out at www.nebiolab.com

Pharmasset, Inc.
Director, Medicinal Chemistry
2007 - June 2009 (2 years)

Synthesis of nucleoside prodrugs for the treatment of HCV. Discovery and development of antiviral agents. Directed the Medicinal Chemistry of the HCV drug discovery portfolio and played key role in nominating nucleoside prodrugs, one of them became a very successful HCV cure drug.
Co-authored in 30 presentations/publications/patents/patent applications from this HCV research work.

Bayer Health Care
Principal Research Scientist II
January 1999 - January 2007 (8 years 1 month)

Medicinal Chemistry, Kinase Inhibitors - broad spectrum and selective, Novel Cell Cycle Inhibitors, High-Speed Synthesis, Novel Lead Generation, Lead Optimization, Cancer, Diabetes, Obesity, Contributed to optimization of leads to NCEs.

Initiated the Chemistry effort on the early research project of the recently approved drug Aliqopa (copanlisib) to treat patients with relapsed follicular lymphoma.

Synaptic Pharmaceutical Corporation

Principal/Senior Research Scientist

June 1993 - December 1998 (5 years 7 months)

GPCR antagonists, agonists, produced sub-nanomolar leads, very selective compounds with good PK and safety profile. Lead generation and optimization. Worked on multiple chemical classes of heterocyclic compounds.

Education

Purdue University

Postdoctoral, Medicinal Chemistry · (1999 - 2001)

University of Illinois at Chicago

Postdoctoral, Medicinal Chemistry, Drug design and synthesis, computer modeling · (2001 - 2003)

University of California, Davis

Research Associate, Bioorganic and Medicinal Chemistry · (1998 - 1999)

University of Madras

Doctor of Philosophy (Ph.D.), Organic/Medicinal Chemistry · (1979 - 1983)